Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors
- PMID: 16392821
- DOI: 10.1021/jm050769s
Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors
Abstract
A novel series of muscarinic receptor ligands of the hexamethonio-type was prepared which contained, on one side, the phthalimidopropane or 1,8-naphthalimido-2,2-dimethylpropane moiety typical for subtype selective allosteric antagonists and, on the other, the acetylenic fragment typical for the nonselective orthosteric muscarinic agonists oxotremorine, oxotremorine-M, and related muscarinic agonists. Binding experiments in M(2) receptors using [(3)H]N-methylscopolamine as an orthosteric probe proved an allosteric action of both groups of hybrids, 7a-10a and 8b-10b. The difference in activity between a-group and b-group hybrids corresponded with the activity difference between the allosteric parent compounds. In M(1)-M(3) muscarinic isolated organ preparations, most of the hybrids behaved as subtype selective antagonists. [(35)S]GTPgammaS binding assays using human M(2) receptors overexpressed in CHO cells revealed that a weak intrinsic efficacy was preserved in 8b-10b. Thus, attaching muscarinic allosteric antagonist moieties to orthosteric muscarinic agonists may lead to hybrid compounds in which functions of both components are mixed.
Similar articles
-
Synthesis and in vitro pharmacology of novel heterocyclic muscarinic ligands.Farmaco. 2003 Sep;58(9):739-48. doi: 10.1016/S0014-827X(03)00113-7. Farmaco. 2003. PMID: 13679167
-
Novel oxotremorine-related heterocyclic derivatives: Synthesis and in vitro pharmacology at the muscarinic receptor subtypes.Bioorg Med Chem. 2007 Dec 15;15(24):7626-37. doi: 10.1016/j.bmc.2007.09.003. Epub 2007 Sep 11. Bioorg Med Chem. 2007. PMID: 17889543
-
Muscarinic allosteric enhancers of ligand binding: pivotal pharmacophoric elements in hexamethonio-type agents.J Med Chem. 2005 Mar 24;48(6):2212-7. doi: 10.1021/jm049616f. J Med Chem. 2005. PMID: 15771463
-
Novel M(1) allosteric ligands: a patent review.Expert Opin Ther Pat. 2012 Dec;22(12):1385-98. doi: 10.1517/13543776.2012.731395. Epub 2012 Oct 23. Expert Opin Ther Pat. 2012. PMID: 23092292 Review.
-
Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs.Mol Interv. 2009 Jun;9(3):125-35. doi: 10.1124/mi.9.3.6. Mol Interv. 2009. PMID: 19592673 Review.
Cited by
-
Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor.Br J Pharmacol. 2013 May;169(2):357-70. doi: 10.1111/bph.12003. Br J Pharmacol. 2013. PMID: 23062057 Free PMC article.
-
Ligand Binding Ensembles Determine Graded Agonist Efficacies at a G Protein-coupled Receptor.J Biol Chem. 2016 Jul 29;291(31):16375-89. doi: 10.1074/jbc.M116.735431. Epub 2016 Jun 13. J Biol Chem. 2016. PMID: 27298318 Free PMC article.
-
Emerging paradigms in GPCR allostery: implications for drug discovery.Nat Rev Drug Discov. 2013 Aug;12(8):630-44. doi: 10.1038/nrd4052. Nat Rev Drug Discov. 2013. PMID: 23903222 Review.
-
Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs.Eur J Pharmacol. 2015 Sep 15;763(Pt B):196-205. doi: 10.1016/j.ejphar.2015.05.013. Epub 2015 May 14. Eur J Pharmacol. 2015. PMID: 25981303 Free PMC article. Review.
-
Rational design of dualsteric GPCR ligands: quests and promise.Br J Pharmacol. 2010 Mar;159(5):997-1008. doi: 10.1111/j.1476-5381.2009.00601.x. Epub 2010 Feb 5. Br J Pharmacol. 2010. PMID: 20136835 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Chemical Information